Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals.
The global interleukin inhibitors market is expected to grow from $17.73 billion in 2020 to $19.88 billion in 2021 at a compound annual growth rate (CAGR) of 12.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $32 billion in 2025 at a CAGR of 13%.
The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them. These interleukin inhibitors are used for the treatment of autoimmune and inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease
The interleukins inhibitors market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, others. It is also segmented by application into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, others and by application into hospital pharmacies, retail pharmacies, online pharmacies.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
High costs associated with biological therapy are hampering the interleukin inhibitors market.Biologic treatment that has revolutionized the care of psoriasis patients is expensive than the other treatments.
The total annual cost ranged from $2,077 to US $13,132 for psoriasis and from $10,924 to $17,050 for psoriatic arthritis, per patient.As of 2020, biologics treatment cost was around $10,000 to $30,000 per year.
The higher price of biologics and low healthcare expenditure in developing countries is, therefore, likely to hinder the market growth.
An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitors market.Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses preventing damage to the host, and maintain normal tissue homeostasis.
There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis.Among these, 20 molecules are in Phase III clinical trials.
These growing numbers of pipeline drugs will drive the interleukin inhibitor market upon approval.
Patent expiry of biologic drugs is opening opportunities for biosimilar drugs, which are a cheap alternative.Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors.
For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx) among others are in development by Mabpharm, NeuClone Pharmaceuticals Ltd, Gedeon Richter, and Bio-Thera Solutions, respectively.Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biologic therapy, and access to treatment may be limited for several reasons including higher treatment costs.
This factor coupled with rapid advances in biotechnology and analytical sciences, which ensure comparability of biosimilars to biologic drugs, drive the trend for biosimilars.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Sep 2021
Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs and Promega Corporation. The global protein expression market is expected to grow from $2.01 billion in 2020 to $2.13 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth...
Recombinant Protein market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Recombinant Protein Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Recombinant Protein types, applications. Further, Recombinant...
Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective This report provides you with a landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technology...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the flow cytometry market are Beckman Coulter, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher and Luminex. The global flow cytometry market is expected to grow from $4.11 billion in 2020 to $4.52 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming...
Global Academic and Non-Profit Partnering Terms and Agreements 2015 to 2021 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This...
The Asia Pacific biopharmaceutical tubing market is expected to reach US$ 903.19 million by 2028 from US$ 487.50 million in 2021; it is estimated to grow at a CAGR of 9.2% from 2021 to 2028. The growth of the market is attributed to key factors such as increasing elderly population in world and proliferation of healthcare sector in...
The North America biopharmaceutical tubing market is expected to reach US$ 3,090.82 million by 2028 from US$ 1,803.70 million in 2021; it is estimated to grow at a CAGR of 8.0% from 2021 to 2028. The growth of the market is attributed to some key driving factors such as increasing elderly population in world, and rising demand for minimally...
The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness. Regulatory approvals and other...
120 pages •
By Infiniti Research Limited
• Jul 2021
Global Chromatography Resins Market 2021-2025 The analyst has been monitoring the chromatography resins market and it is poised to grow by $ 1.22 bn during 2021-2025, progressing at a CAGR of almost 9% during the forecast period. Our report on chromatography resins market provides a holistic analysis, market size and forecast,...
The global pharmaceutical CMO market was valued at USD 120.29 billion in 2020, and it is expected to reach USD 195.70 billion by 2026, registering a CAGR of 7.85% from 2021 to 2026. COVID-19 pandemic has had a beneficial effect on contract manufacturing services overall. There were multiple opportunities for CMOs in clinical trial manufacturing,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.